Polynucleotide Fragments of an Infectious Human Endogenous Retrovirus

a technology polynucleotide fragment, which is applied in the field can solve the problems that the infection of human endogenous retrovirus cannot be isolated or detected so far, and achieve the effect of improving antisense agent and greater resistance to enzymatic degradation

Inactive Publication Date: 2008-01-10
BAXTER HEALTHCARE SA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0137] Still preferred, said antigen is immobilized to a solid support. This allows an easy handling of said kit and the method can be carried out immediately without prior preparations.
[0138] According to a further embodiment of the present invention a PNA molecule is provided which comprises a base sequence complementary to the sequence of said polynucleotide molecule as defined above according to the present invention. PNA (peptide nucleic acid) is a DNA like sequence, the nucleic basis being bound to a pseudo peptide backbone. PNA generally hybridizes with complementary DNA, RNA or DNA polymers by Watson-Creek base ...

Problems solved by technology

This is particularly surprising due to the fact that human endogenous retroviruses have been known and described for more than 30 years, however, even th...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polynucleotide Fragments of an Infectious Human Endogenous Retrovirus
  • Polynucleotide Fragments of an Infectious Human Endogenous Retrovirus
  • Polynucleotide Fragments of an Infectious Human Endogenous Retrovirus

Examples

Experimental program
Comparison scheme
Effect test

example 1

Human Melanoma Cells Contain RT Activity in their Supernatants

[0157] To detect extracellular virions, supernatants from the melanoma cell lines SKMel-28, SKMel-1, 518A2 were analyzed, as well as primary melanoma cells for pelletable RT. Supernatants from cultured human neonatal melanocytes (NHEM) served as controls. Cell-free supernatants from approximately 106 cells were concentrated by centrifugation. The RT activity of the resulting pellets was analyzed by F-PERT assay.

[0158] Supernatants from melanoma cell lines, and normal human melanocytes were centrifuged at 3000×g at 4° C. and sterile-filtered through a 0.22 μm low-protein membrane (Nunc) to remove cells and cellular debris. The clarified supernatants were centrifuged for 20 min at 250000×g at 4° C. in a Beckman SW50.1 rotor. Pellets were rinsed with phosphate-buffered saline (PBS) and centrifuged for 15 min at 250000×g and resuspended. The resulting particle suspensions were used as an enzyme source for RT assays.

[0159] ...

example 2

Human Melanoma Cell Derived Particles Package Sequences with High Homology to HERV-K

[0161] Retroviral pol genes are generally the most conserved sequences among retroviruses. In an attempt to analyze the particle preparations on a molecular level, a sequence was amplified by using degenerate primers corresponding to conserved sequences of the pol gene. Particle preparations of the melanoma cell line 518A2 and SK-Mel28 were used for RT-PCR analysis. Particles were treated with DNase, to remove contaminating traces of genomic DNA.

[0162] Oligonucleotide primers 3′ABDPOLS 5′dCATTCCTTGTGGTAAAACTTTCCA[T / C]TG 3′ (SEQ ID NO:57) and 5′ABDPOLAS 5′dCCCCTTGGAATACTCCTGTTTT[T / C]TG 3′ (SEQ ID NO:58) (Codon Genetic Systems, Austria), derived from conserved regions within the retroviral reverse transcriptase (RT), were adopted from Medstrand and Blomberg. In order to release viral RNA, the particle suspension was transferred to a 0.5 ml polypropylene microcentrifuge tube (Sorensen Inc., USA). Then...

example 3

Human Melanoma Derived Particles Contain Mature gag and env Proteins

[0165] Particles derived from SK-Mel28 melanoma cells were purified on iodixanol-cushions and analyzed for the presence of HERV-K-specific env and gag proteins in Western blots.

[0166] Iodixanol-cushion purified particles from SK-Mel28 supernatants were pelleted, resuspended in PBS and analyzed. The amount of soluble proteins was quantified by means of a modified Bradford analysis (Bio-rad, Richmond Calif.). 5 μg of total protein was applied per lane and separated by SDS-PAGE (10%). Proteins were transferred to PVDF membranes (Millipore, Bedford, Mass.) by Western blotting, and generated blots were incubated with the gag- and env-specific antisera. The membranes were washed twice with blocking solution and HERV-K-specific proteins were detected with an alkaline-phosphatase-conjugated second-step antibody.

[0167] The envelope (env) gene of retroviruses displays an ORF for the surface protein (SU) and a membrane span...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. "Fragments" according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a divisional of co-pending U.S. application Ser. No. 10 / 490,920 filed 26 Mar. 2004, which is a national phase application under 35 U.S.C. § 371 of International Application No. PCT / EP02 / 10899 filed 27 Sep. 2002, which claims priority to Austrian Application No. A 1539 / 2001 filed 27 Sep. 2001, the contents of which are incorporated herein by reference in their entirety.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to human endogenous retroviruses, fragments thereof, a biologically functional vector comprising sequences of said retrovirus. [0004] 2. Description of Related Art [0005] Endogenous retroviruses (ERVs) are integral parts in the genomes of many, if not of all, species. ERVs most probably resulted from infection of germ line cells with exogenous retroviruses and subsequent fixation of their genetic information in the host genome. [0006] Many types of human en...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K35/76A61K39/21C07K16/08A61K39/395A61K38/00A61K39/00C07K14/15C12N7/00C12N15/48G01N33/569G01N33/574
CPCA61K38/00A61K39/00A61K2039/5254C07K14/005G01N2333/15C12N2740/10021C12N2740/10022G01N33/56983G01N33/5743C12N7/00
Inventor WOLFF, KLAUSPEHAMBERGER, HUBERTGRASSAUER, ANDREASMUSTER, THOMAS
Owner BAXTER HEALTHCARE SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap